timothy sykes logo
Natera Stock Jumps After Earnings Beat And Guidance Hike Thumbnail
G Google News

Natera Stock Jumps After Earnings Beat And Guidance Hike

JACK KELLOGG•UPDATED AUG. 7, 2026, 4:38 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Natera Inc. stocks have been trading up by 21.34 percent following strong clinical trial results that boosted investor optimism.

What Traders Need To Know

  • Q2 revenue came in at $752.8M, far above the $661.2M consensus, signaling stronger-than-modeled demand.
  • The company posted a Q2 loss of $0.47 per share versus a $0.49 loss expected, showing slightly better cost control.
  • Full-year 2026 revenue guidance was raised to $2.85B–$2.91B, now above the roughly $2.8B consensus.
  • Shares ripped more than 12% in after-hours trading after the Q2 beat and guidance raise, highlighting aggressive upside momentum.
  • The Signatera MRD test was submitted to Japan’s PMDA for muscle-invasive bladder cancer, expanding on existing colorectal cancer approval and building Natera’s Japanese oncology presence.

Candlestick Chart

Weekly Update Aug 03 – Aug 07, 2026: On Friday, August 07, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 21.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Natera occupies a leading growth position in molecular diagnostics, with revenue of ~$2.3B and 40%+ 3–5 year CAGR, supported by a 65% gross margin that validates pricing power and scale. However, EBIT margin of roughly -13% and ROE around -15% highlight a still-loss-making model, with net income of -$85M in Q1 2026. The balance sheet is solid versus diagnostics peers: low leverage (debt/equity 0.13), current ratio ~3x, and over $1.0B in cash supporting continued investment.

Technically, NTRA is in a powerful uptrend, with the stock moving from ~$270 to $321 in four sessions, including a momentum gap from $265.38 to an intraday high of $330 and strong follow-through to new highs. Intraday 5-minute action shows heavy volume concentration between $300–310, establishing $300 as near-term support. For active traders, $300 is the key actionable pivot: buy pullbacks toward $300 with a stop near $285 and upside potential back to the $330 area.

Fundamentally and thematically, Natera is outperforming both Healthcare and Diagnostics & Screening peers on growth, underpinned by strong Q2 revenue of $752.8M, a raised 2026 guide to $2.85–2.91B, and expanding oncology opportunities (Signatera PMDA companion diagnostic submission in bladder cancer, on top of CRC and U.S. FDA traction). Despite ongoing losses, improving scale and robust liquidity justify a premium multiple. I assign a 12-month target of $360, with support at $300 and resistance near $340.

More Breaking News

Quick Financial Overview

Natera Inc. (NTRA) just printed a textbook high-momentum earnings move. Q2 revenue of $752.8M crushed the $661.2M consensus, confirming strong demand and record testing volumes, particularly in oncology. The company is still losing money, with a Q2 loss of $0.47 per share, but even that was slightly better than the expected $0.49 loss, pointing to gradual operating leverage rather than sudden profitability.

On guidance, Natera Inc. raised its 2026 revenue outlook to a range of $2.85B–$2.91B, up from $2.74B–$2.82B and now above the roughly $2.8B Street view. That kind of raise is exactly what drives repricing in high-growth names. The underlying fundamentals back the story: trailing revenue of about $2.31B is growing at over 40% per year, supported by a hefty 65.1% gross margin. At the same time, negative EBIT margins near -13% and returns on equity and assets still deep in the red tell traders this remains a growth-over-profits setup.

The balance sheet looks reasonably sturdy for this style of name. Natera Inc. carries a low total-debt-to-equity ratio around 0.13 and a current ratio near 3, giving it room to ride out volatility. Cash flow is improving, with positive free cash flow of roughly $18M in the latest reported quarter, even as net income stayed negative. The valuation is rich, with a price-to-sales multiple near 15.7 and price-to-book over 22, meaning NTRA is priced for sustained high growth and flawless execution.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”